BNGO Nov 2024 1.000 call
| Previous Close | 0.4000 |
| Open | 0.4000 |
| Bid | 0.0000 |
| Ask | 0.5000 |
| Strike | 1.00 |
| Expire Date | 2024-11-15 |
| Day's Range | 0.4000 - 0.4000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 112 |
GlobeNewswireBionano Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy
Three peer-reviewed publications collectively illustrate the building support for optical genome mapping (OGM) as a tool for cell and gene therapy development that allows researchers in academic medical centers and biopharmaceutical companies to assess genome integrity in therapeutic cell lines like chimeric antigen receptor-modified T cells (CAR-T), stem cells, and cell lines used for translational research in unraveling genetic causes of Alzheimer’s diseaseTaken together, the publications illu
Insider MonkeyBionano Genomics, Inc. (NASDAQ:BNGO) Q1 2024 Earnings Call Transcript
Bionano Genomics, Inc. (NASDAQ:BNGO) Q1 2024 Earnings Call Transcript May 8, 2024 Bionano Genomics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to the Bionano First Quarter 2024 Earnings Conference Call. Today’s conference is being […]
- GlobeNewswire
Bionano Announces Series of Major Advancements to its Suite of Computational Tools for Comprehensive Cancer Analysis
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced significant upgrades to its suite of computational tools for comprehensive cancer analysis. These advancements to the company’s VIA™ software solution enhance the detection and interpretation of aneusomies, and improve the analysis, visualization, interpretation, and reporting of data types including optical genome mapping (OGM), next generation sequencing, and microarray, for comprehensive assessme
